9/21/2010

India-based Ranbaxy Laboratories won exclusive rights to sell a generic version of Eisai Co.'s Alzheimer's drug Aricept. The FDA said Teva Pharmaceutical Industries, which had an approval to sell the drug, must delay 180 days before competing with Ranbaxy.

Full Story:
Bloomberg

Related Summaries